New Content  edit
Get The App!

Loading the player...
Cabozantinib for Late Stage Kidney Cancer
Share URL
Embed Code
Share by Email
Send to social websites
Report this video as inappropriate You can report this video if you think it to be inappropriate, we will review your submission soon. If your reason is not listed here, like copyright infringements, please contact us directly by email. Select your reason
Sexual Content Violent or Repulsive Content
Hateful or Abusive Content Harmful Dangerous Acts
Child Abuse Spam
Cometriq (cabozantinib) is already approved for thyroid cancer and is showing promise for late stage kidney cancer. Interview with Guru Sonpavde conducted at the 2014 ASCO meeting by Dr. Sumanta (Monty) Pal.Oncology.TV would like to gratefully acknowledge for the content of this interview.